Optimizing iPSC therapies: strategies for safe, cost-effective, and scalable manufacturing
K Bruce, K Bharti, I Barbaric et al
Achieving rapid microbiological monitoring in fill-finish with biofluorescent particle counters: a collaborative case study
M Dingle, A Carwell, M J. Miller et al
GMP or not? Understanding raw material quality grades and requirements for ATMP manufacturing
Lili Belcastro, Basak Clements, Claire Wartel
Modernizing viral clearance study strategy: regulatory updates and industry best practices
Audrey Chang, Kathleen Kenney
From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development
Audrey Chang, Joe Newcome
Emerging global trends and regulatory opportunities in cell therapies for cancer
Kim Watanabe, Sushama Sankpal, Kasey Kime
Revolutionizing cell and gene therapy with digitalization: a panel discussion with industry leaders
Caitlin Harrison, Rebecca Street-Howards, Kanchan Deshpande
Preventing cross-contamination in cell therapy production
Josh Ludwig, Mary Kay Bates
Considerations in leveraging the Universal AAV Standard for dPCR to assess AAV genomes quantity and quality
Andrzej Noyszewski, Alex Deiulio
Advancing viral vector manufacturing with innovation: the importance of the cell line
Marguerite Campbell, Brian Tomkowicz
Discover the road to success for viral vector production: strategies, insights, and regulatory considerations
Samira Shore, Anne Gilbert, Jesse Bishop
Mastering the journey from initial method transfer to successful lot release for cell & gene therapies
A Chang, H Malicki, J Cheung et al
Considerations to optimize and act upon long-term follow-up studies for cell and gene therapies
K Wonnacott, L Pelloso, D Takefman et al
Strategic raw material selection for cell therapy commercialization
Kasey Kime, Lili Belcastro, Kyle Hondorp
How patient focus drives clinical trial results: the intersection of sponsor, CRO, site, and patient
K Kane, K Nealon, B Bratrude et al
Exploring and overcoming the challenges of cell and gene-modified cell therapy CMC
Julia Sable, Larry Bellot, Karen Doucette
Accelerating your gene therapy to patients: not all platforms are created equal
George Buchman, Thomas VanCott